Effect of SLCO1B1 T521C on Statin-induced Myotoxicity: A Systematic Review and Meta-analysis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: This study was performed to clarify the effect of SLCO1B1 T521C on statin-induced myotoxicity. Methods: ThePubMed, Embase, Ovid, and Cochrane Library databases were searched for all published studies between database inception andApril 2018. Using Review Manager 5, the pooled odds ratio (OR) and corresponding 95% confidence interval (CI) were determinedto assess the effect of SLCO1B1 T521C on statin-induced myotoxicity by using different genetic models. Results: Elevenobservational studies and one randomized controlled trial were included in the meta-analysis. The pooled analysis showed that theincidence of statin-induced myotoxicity was significantly associated with the SLCO1B1 521C variant allele. Among patients usingstatins, the incidence of myotoxicity was higher in those carrying the 521TC or 521CC variant than in those carrying the 521TTvariant in the dominant model (TC + CC vs TT, OR: 1.57; 95% CI: 1.20, 2.05; p = 0.001). The 521TC genotype was associated witha higher risk of myotoxicity than the 521TT genotype (OR: 1.42; 95% CI: 1.09, 1.86; p = 0.009). Furthermore, the incidence ofmyotoxicity was higher in 521CC carriers than in 521TC carriers (OR: 1.40; 95% CI: 1.06, 1.83; p = 0.02) and noticeably higher in521CC carriers than in 521TT carriers (OR: 2.26; 95% CI: 1.23, 4.17; p = 0.009). Conclusion: The identification of individuals with theSLCO1B1 521C variant allele prior to the initiation of statin therapy might be useful to predict the risk of toxicity development,determine the individual dose, and prevent myotoxicity.
Abstract
Background: This study was performed to clarify the effect of SLCO1B1 T521C on statin-induced myotoxicity. Methods: ThePubMed, Embase, Ovid, and Cochrane Library databases were searched for all published studies between database inception andApril 2018. Using Review Manager 5, the pooled odds ratio (OR) and corresponding 95% confidence interval (CI) were determinedto assess the effect of SLCO1B1 T521C on statin-induced myotoxicity by using different genetic models. Results: Elevenobservational studies and one randomized controlled trial were included in the meta-analysis. The pooled analysis showed that theincidence of statin-induced myotoxicity was significantly associated with the SLCO1B1 521C variant allele. Among patients usingstatins, the incidence of myotoxicity was higher in those carrying the 521TC or 521CC variant than in those carrying the 521TTvariant in the dominant model (TC + CC vs TT, OR: 1.57; 95% CI: 1.20, 2.05; p = 0.001). The 521TC genotype was associated witha higher risk of myotoxicity than the 521TT genotype (OR: 1.42; 95% CI: 1.09, 1.86; p = 0.009). Furthermore, the incidence ofmyotoxicity was higher in 521CC carriers than in 521TC carriers (OR: 1.40; 95% CI: 1.06, 1.83; p = 0.02) and noticeably higher in521CC carriers than in 521TT carriers (OR: 2.26; 95% CI: 1.23, 4.17; p = 0.009). Conclusion: The identification of individuals with theSLCO1B1 521C variant allele prior to the initiation of statin therapy might be useful to predict the risk of toxicity development,determine the individual dose, and prevent myotoxicity.
참고문헌 (50)
- Mihaylova B, "The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials", Lancet, 380(9841), pp.581~590 (2012)
- "BIT Druginfo"[URL]
- "Drugs@FDA"[URL]
- Sirtori CR., "The pharmacology of statins", Pharmacol Res, 88, pp.3~11 (2014)
- Wolfrum S, "Endothelium-dependent effects of statins", Arterioscler Thromb Vasc Biol, 23(5), pp.729~736 (2003)
- Tousoulis D, "Assessing inflammatory status in cardiovascular disease", Heart, 93(8), pp.1001~1007 (2007)
- Tousoulis D, "Innate and adaptive inflammation as a therapeutic target in vascular disease : the emerging role of statins", J Am Coll Cardiol, 63(23), pp.2491~2502 (2014)
- Stroes ES, "Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management", Eur Heart J, 36, pp.1012~1022 (2015)
- du Souich P, "Myotoxicity of statins: mechanism of action", 175, pp.1~16 (2017)
- Young JM, "Effect of coenzyme Q(10)supplementation on simvastatin-induced myalgia", Am J Cardiol, 100(9), pp.1400~1403 (2007)
- 최혜경, "Effect of Coenzyme Q10 Supplementation in Statin-Treated Obese Rats", Biomolecules & Therapeutics, 24(2), pp.171~177 (2016), 한국응용약물학회
- Tomaszewski M, "Statin-induced myopathies", Pharmacol Rep, 63(4), pp.859~866 (2011)
- Sathasivam S, "Statin induced myotoxicity", Eur J Intern Med, 23(4), pp.317~324 (2012)
- Schech S, "Risk factors for statin-associated rhabdomyolysis", Pharmacoepidemiol Drug Saf, 16(3), pp.352~358 (2007)
- El-Salem K, "Prevalence and risk factors of muscle complications secondary to statins", Muscle Nerve, 44(6), pp.877~881 (2011)
- Feng Q, "Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions", Pharmacogenomics, 13(5), pp.579~594 (2012)
- König J, "A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane", Am J Physiol Gastrointest Liver Physiol, 278(1), pp.G156~G164 (2000)
- Niemi M, "Role of OATP transporters in the disposition of drugs", Pharmacogenomics, 8(7), pp.787~802 (2007)
- Niemi M, "Organic anion transporting polypeptide 1B1 : a genetically polymorphic transporter of major importance for hepatic drug uptake", Pharmacol Rev, 63(1), pp.157~181 (2011)
- Hou Q, "Association between SLCO1B1 Gene T521C polymorphism and statin-related myopathy risk: A meta-analysis of case-control studies", Medicine (Baltimore), 94(37), pp.e1268~ (2015)
- Danik JS, "Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy", Am Heart J, 165(6), pp.1008~1014 (2013)
- Sessa M, "Preventable statin adverse reactions and therapy discontinuation. What can we learn from the spontaneous reporting system?", Expert Opin Drug Saf, 17(5), pp.457~465 (2018)
- Pasternak RC, "ACC", AHA, J Am Coll Cardiol, pp.2002, 40[DOI]
- de Lemos JA, "Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes : phase Z of the A to Z trial", JAMA, 292(11), pp.1307~1316 (2004)
- "The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses"[URL]
- Zheng JS, "Intake of fish and marine n-3 polyunsaturated fatty acids and risk of breast cancer: meta-analysis of data from 21 independent prospective cohort studies", BMJ, 346, pp.f3706~ (2013)
- Zhang BB, "Association between the MDR1gene variant C3435T and risk of leukaemia : a meta-analysis", Eur J Cancer Care(Engl), 22(5), pp.617~625 (2013)
- Huedo-Medina TB, "Assessing heterogeneity in meta-analysis: Q statistic or I2 index?", Psychol Methods, 11(2), pp.193~206 (2006)
- Sutton AJ, "Empirical assessment of effect of publication bias on meta-analyses", BMJ, 320(7249), pp.1574~1577 (2000)
- Voora D, "The SLCO1B1*5 genetic variant is associated with statin-induced side effects", J Am Coll Cardiol, 54(17), pp.1609~1616 (2009)
- Linde R, "The role of vitamin D and SLCO1B1*5 gene polymorphism in statin-associated myalgias", Dermatoendocrinol, 2(2), pp.77~84 (2010)
- Santos PC, "SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia", Eur J Clin Pharmacol, 68(3), pp.273~279 (2012)
- Donnelly LA, "Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes : a go-DARTS study", Clin Pharmacol Ther, 89(2), pp.210~216 (2011)
- Link E, "SLCO1B1 variants and statininduced myopathy-a genomewide study", N Engl J Med, 359, pp.789~799 (2008)
- Marciante KD, "Cerivastatin, genetic variants, and the risk of rhabdomyolysis", Pharmacogenet Genomics, 21(5), pp.280~288 (2011)
- Brunham LR, "Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin", Pharmacogenomics J, 12(3), pp.233~237 (2012)
- Carr DF, "SLCO1B1 genetic variant associated with statin-induced myopathy : a proof-of-concept study using the clinical practice research datalink", Clin Pharmacol Ther, 94(6), pp.695~701 (2013)
- Mirošević Skvrce N, "ABCG2 gene polymorphisms as risk factors for atorvastatin adverse reactions : a case-control study", Pharmacogenomics, 16(8), pp.803~815 (2015)
- Liu JE, "SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients : a nested case-control study", Eur J Clin Pharmacol, 73(11), pp.1409~1416 (2017)
- Bakar NS, "Genetic and Clinical Factors Are Associated With Statin-Related Myotoxicity of Moderate Severity : A Case-Control Study", Clin Pharmacol Ther, 104(1), pp.178~187 (2018)
- Ferrari M, "Association between statininduced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2", Eur J Clin Pharmacol, 70(5), pp.539~547 (2014)
- Pasanen MK, "SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid", Pharmacogenet Genomics, 16(12), pp.873~879 (2006)
- Parker BA, "Effect of statins on skeletal muscle function", Circulation, 127(1), pp.96~103 (2013)
- Jiang J, "Association between SLCO1B1-521T >C and-388A > G polymorphisms and risk of statin-induced adverse drug reactions : A meta-analysis", Springerplus, 5(1), pp.1368~ (2016)
- Kullak-Ublick GA, "Organic anion-transporting polypeptide B(OATP-B)and its functional comparison with three other OATPs of human liver", Gastroenterology, 120(2), pp.525~533 (2001)
- Zaïr ZM, "Pharmacogenetics of OATP (SLC21", SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney, 2008, pp.9(5), 597~624
- Kalliokoski A, "Impact of OATP transporters on pharmacokinetics", Br J Pharmacol, 158(3), pp.693~705 (2009)
- Abd TT, "Statin-induced myopathy : a review and update", Expert Opin Drug Saf, 10(3), pp.373~387 (2011)
- Vildhede A, "Hepatic uptake of atorvastatin : influence of variability in transporter expression on uptake clearance and drug-drug interactions", Drug Metab Dispos, 42(7), pp.1210~1218 (2014)